Prediction role of a novel biomarker ST2 in risk assessment of adverse cardiovascular events in chronic heart failure with preserved and intermediate ejection fraction after myocardial revascularization
Aim. To evaluate prediction role of the biomarkers soluble ST2 (sST2) and natriuretic hormone N-terminal propeptide (NT-proBNP) in risk assessment of adverse cardiovascular events (ACVE) in coronary heart disease patients (CHD) with chronic heart failure (CHF) after myocardial revascularization.Mate...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2018-10-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/755 |
| _version_ | 1797882454333194240 |
|---|---|
| author | E. V. Grakova A. T. Teplyakov K. V. Kopieva Sh. D. Akhmedov O. N. Ogurkova M. V. Soldatenko |
| author_facet | E. V. Grakova A. T. Teplyakov K. V. Kopieva Sh. D. Akhmedov O. N. Ogurkova M. V. Soldatenko |
| author_sort | E. V. Grakova |
| collection | DOAJ |
| description | Aim. To evaluate prediction role of the biomarkers soluble ST2 (sST2) and natriuretic hormone N-terminal propeptide (NT-proBNP) in risk assessment of adverse cardiovascular events (ACVE) in coronary heart disease patients (CHD) with chronic heart failure (CHF) after myocardial revascularization.Material and methods. Totally, 87 patients included (72 males) with CHD and CHF I-III functional class by NYHA with ejection fraction of the left ventricle (LVEF) 63 [55; 65]%, mean age 63 [57; 69] y.o. Levels of sST2 and NT-proBNP in plasma were measured by immune enzyme assay before myocardial revascularization.Results. In 12 months of prospective follow-up, patients were selected to 2 groups according to clinical course of CHF. To the group I the patients included (n=35) with ACVE, group II (b=52) — with none. It was found that in the group I the level of sST2 was higher by 41,5% (p<0,001) and reached 46,78 [37,88; 64,96] ng/mL, and in the group II — 27,39 [23,02; 35,4] ng/mL. Concentration of NT-proBNP in the group with ACVE was 2,5 times (p=0,004) higher comparing with group II and reached 189,21 [74,46; 580,79] and 73,58 [26,64; 155,77] pg/mL, respectively. In ROC-analysis it was found that the level of sST2 ≥34,18 ng/mL (sensitivity — 90,6%, specificity — 75,0%, AUC — 0,88, р<0,0001) and level of NT-proBNP ≥276,96 pg/mL (sensitivity — 88,4%, specificity — 43,7%, AUC — 0,64, р<0,004) can be regarded as markers of ACVE during 12 months in CHD and CHF patients after revascularization. Also, together these two markers increase predictive significance of the analysis (sensitivity — 92,6%, specificity — 77,1%, AUC — 0,90, р<0,0001).Conclusion. Therefore, the preprocedural level of sST2 can be regarded as non-invasive marker for prediction of ACVE. Combination of sST2 and NT-proBNP shows higher diagnostic sensitvity and specificity for prediction of adverse CHF course. |
| first_indexed | 2024-04-10T03:34:59Z |
| format | Article |
| id | doaj.art-471acb8dfdc54530b9259b61c7b8b11c |
| institution | Directory Open Access Journal |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| last_indexed | 2024-04-10T03:34:59Z |
| publishDate | 2018-10-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj.art-471acb8dfdc54530b9259b61c7b8b11c2023-03-13T07:23:27Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252018-10-01175404610.15829/1728-8800-2018-5-40-46578Prediction role of a novel biomarker ST2 in risk assessment of adverse cardiovascular events in chronic heart failure with preserved and intermediate ejection fraction after myocardial revascularizationE. V. Grakova0A. T. Teplyakov1K. V. Kopieva2Sh. D. Akhmedov3O. N. Ogurkova4M. V. Soldatenko5Научно-исследовательский институт кардиологии, ФГБНУ “Томский национальный исследовательский медицинский центр” Российской академии наукНаучно-исследовательский институт кардиологии, ФГБНУ “Томский национальный исследовательский медицинский центр” Российской академии наукНаучно-исследовательский институт кардиологии, ФГБНУ “Томский национальный исследовательский медицинский центр” Российской академии наукНаучно-исследовательский институт кардиологии, ФГБНУ “Томский национальный исследовательский медицинский центр” Российской академии наукНаучно-исследовательский институт кардиологии, ФГБНУ “Томский национальный исследовательский медицинский центр” Российской академии наукНаучно-исследовательский институт кардиологии, ФГБНУ “Томский национальный исследовательский медицинский центр” Российской академии наукAim. To evaluate prediction role of the biomarkers soluble ST2 (sST2) and natriuretic hormone N-terminal propeptide (NT-proBNP) in risk assessment of adverse cardiovascular events (ACVE) in coronary heart disease patients (CHD) with chronic heart failure (CHF) after myocardial revascularization.Material and methods. Totally, 87 patients included (72 males) with CHD and CHF I-III functional class by NYHA with ejection fraction of the left ventricle (LVEF) 63 [55; 65]%, mean age 63 [57; 69] y.o. Levels of sST2 and NT-proBNP in plasma were measured by immune enzyme assay before myocardial revascularization.Results. In 12 months of prospective follow-up, patients were selected to 2 groups according to clinical course of CHF. To the group I the patients included (n=35) with ACVE, group II (b=52) — with none. It was found that in the group I the level of sST2 was higher by 41,5% (p<0,001) and reached 46,78 [37,88; 64,96] ng/mL, and in the group II — 27,39 [23,02; 35,4] ng/mL. Concentration of NT-proBNP in the group with ACVE was 2,5 times (p=0,004) higher comparing with group II and reached 189,21 [74,46; 580,79] and 73,58 [26,64; 155,77] pg/mL, respectively. In ROC-analysis it was found that the level of sST2 ≥34,18 ng/mL (sensitivity — 90,6%, specificity — 75,0%, AUC — 0,88, р<0,0001) and level of NT-proBNP ≥276,96 pg/mL (sensitivity — 88,4%, specificity — 43,7%, AUC — 0,64, р<0,004) can be regarded as markers of ACVE during 12 months in CHD and CHF patients after revascularization. Also, together these two markers increase predictive significance of the analysis (sensitivity — 92,6%, specificity — 77,1%, AUC — 0,90, р<0,0001).Conclusion. Therefore, the preprocedural level of sST2 can be regarded as non-invasive marker for prediction of ACVE. Combination of sST2 and NT-proBNP shows higher diagnostic sensitvity and specificity for prediction of adverse CHF course.https://cardiovascular.elpub.ru/jour/article/view/755ишемическая болезнь сердцареваскуляризация миокарданеблагоприятные сердечно-сосудистые событияпрогнозированиебиомаркерысердечная недостаточность |
| spellingShingle | E. V. Grakova A. T. Teplyakov K. V. Kopieva Sh. D. Akhmedov O. N. Ogurkova M. V. Soldatenko Prediction role of a novel biomarker ST2 in risk assessment of adverse cardiovascular events in chronic heart failure with preserved and intermediate ejection fraction after myocardial revascularization Кардиоваскулярная терапия и профилактика ишемическая болезнь сердца реваскуляризация миокарда неблагоприятные сердечно-сосудистые события прогнозирование биомаркеры сердечная недостаточность |
| title | Prediction role of a novel biomarker ST2 in risk assessment of adverse cardiovascular events in chronic heart failure with preserved and intermediate ejection fraction after myocardial revascularization |
| title_full | Prediction role of a novel biomarker ST2 in risk assessment of adverse cardiovascular events in chronic heart failure with preserved and intermediate ejection fraction after myocardial revascularization |
| title_fullStr | Prediction role of a novel biomarker ST2 in risk assessment of adverse cardiovascular events in chronic heart failure with preserved and intermediate ejection fraction after myocardial revascularization |
| title_full_unstemmed | Prediction role of a novel biomarker ST2 in risk assessment of adverse cardiovascular events in chronic heart failure with preserved and intermediate ejection fraction after myocardial revascularization |
| title_short | Prediction role of a novel biomarker ST2 in risk assessment of adverse cardiovascular events in chronic heart failure with preserved and intermediate ejection fraction after myocardial revascularization |
| title_sort | prediction role of a novel biomarker st2 in risk assessment of adverse cardiovascular events in chronic heart failure with preserved and intermediate ejection fraction after myocardial revascularization |
| topic | ишемическая болезнь сердца реваскуляризация миокарда неблагоприятные сердечно-сосудистые события прогнозирование биомаркеры сердечная недостаточность |
| url | https://cardiovascular.elpub.ru/jour/article/view/755 |
| work_keys_str_mv | AT evgrakova predictionroleofanovelbiomarkerst2inriskassessmentofadversecardiovasculareventsinchronicheartfailurewithpreservedandintermediateejectionfractionaftermyocardialrevascularization AT atteplyakov predictionroleofanovelbiomarkerst2inriskassessmentofadversecardiovasculareventsinchronicheartfailurewithpreservedandintermediateejectionfractionaftermyocardialrevascularization AT kvkopieva predictionroleofanovelbiomarkerst2inriskassessmentofadversecardiovasculareventsinchronicheartfailurewithpreservedandintermediateejectionfractionaftermyocardialrevascularization AT shdakhmedov predictionroleofanovelbiomarkerst2inriskassessmentofadversecardiovasculareventsinchronicheartfailurewithpreservedandintermediateejectionfractionaftermyocardialrevascularization AT onogurkova predictionroleofanovelbiomarkerst2inriskassessmentofadversecardiovasculareventsinchronicheartfailurewithpreservedandintermediateejectionfractionaftermyocardialrevascularization AT mvsoldatenko predictionroleofanovelbiomarkerst2inriskassessmentofadversecardiovasculareventsinchronicheartfailurewithpreservedandintermediateejectionfractionaftermyocardialrevascularization |